Our immuno-oncology collaboration with GlaxoSmithKline (GSK) is focused upon the development and commercialization of AnaptysBio-generated checkpoint antagonist antibodies to PD-1, TIM-3 and LAG-3. The exclusively licensed products being advanced by GSK under this partnership include dostarlimab, cobolimab and GSK4074386.
JEMPERLI (dostarlimab) is an anti-PD-1 antagonist antibody currently under development by GSK for multiple oncological disorders, including endometrial cancer, non-small cell lung cancer, ovarian cancer, colorectal cancer and mismatch repair deficient solid tumors. A BLA for JEMPERLI was approved by the FDA in April 2021 for the treatment of advanced or recurrent deficient mismatch repair endometrial cancer (dMMREC). In April 2021, the European Medicines Agency (EMA) granted conditional marketing authorization in the European Union for JEMPERLI for use in women with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer who have progressed on or following prior treatment with a platinum containing regimen, which approval makes JEMPERLI the first anti-PD-1 therapy available for endometrial cancer in Europe. The FDA approved JEMPERLI for a second indication, treatment of mismatch repair deficient cancers on a pan-tumor basis, in August 2021.
Cobolimab, an anti-TIM-3 antagonist antibody, has completed a Phase 1 study and is currently in combination Phase 2 trials with dostarlimab for certain solid tumor indications. GSK4069889, an anti-LAG-3 antagonist antibody, is undergoing Phase 1 studies.
Under the terms of our GSK collaboration, AnaptysBio is entitled to receive an 8-25% royalty upon global net sales of JEMPERLI, where the 8% tier is applicable to annual global net sales below $1 billion while net sales above $1 billion will be paid 12-25% royalty. Royalties upon global net sales of other products under the collaboration, including cobolimab and GSK4069889, will range from 4-8%. A total of $1.1 billion in development, regulatory and commercial milestones are due to AnaptysBio under this collaboration, including an additional $15 million and $165 million in milestone payments upon achievement of certain JEMPERLI regulatory and commercial milestones, respectively.
In October 2021, we announced the signing of a royalty monetization agreement with Sagard Healthcare Royalty Partners where AnaptysBio would receive a $250 million payment upon closing, which is anticipated by the end of 2021, in exchange of JEMPERLI royalties due to AnaptysBio on annual commercial sales below $1 billion and certain future milestones starting October 2021. The aggregate JEMPERLI royalties and milestones to be received by Sagard under this Agreement is capped at certain fixed multiples of the upfront payment based upon time. The closing of the transaction is subject to the satisfaction of customary closing conditions.
GSK has also agreed, starting January 1, 2021, to pay AnaptysBio a 1% royalty on all of GSK’s global net sales of ZejulaTM. In addition, GSK has agreed to pay AnaptysBio a one-time cash payment of $60 million in fourth quarter of 2020.
To access scientific publications on this topic, please click here.
Bristol-Myers Squibb Partnership
Under our collaboration with Bristol-Myers Squibb (BMS) we developed therapeutic antibodies against multiple targets. We granted BMS the option to obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting certain pre-specified parameters pertaining to each target under collaboration. BMS is currently advancing two AnaptysBio-generated anti-inflammatory antibody programs, and has initiated a Phase 1 trial for one of these two antibodies known as CC-90006, a PD-1 agonist antibody, which is indicated for psoriasis.